Please use this identifier to cite or link to this item:
|Title:||Botulinum toxin: A novel therapeutic option for bronchial asthma?|
|Authors:||Lim, E.C.H. |
|Citation:||Lim, E.C.H., Ong, B.K.C., Oh, V.M.S., Seet, R.C.S. (2006). Botulinum toxin: A novel therapeutic option for bronchial asthma?. Medical Hypotheses 66 (5) : 915-919. ScholarBank@NUS Repository. https://doi.org/10.1016/j.mehy.2005.12.015|
|Abstract:||Two components are essential for the development of an attack of bronchial asthma: inflammation and bronchoconstriction, the latter being mediated by smooth muscle contraction. Despite the efficacy of chronic therapy, many asthmatics relapse. Measures to inhibit contraction of the airway smooth muscle, such as vagotomy and thermoablation, may decrease the bronchoconstrictor component of the asthma attack and help to decrease morbidity and mortality from the disease. Botulinum toxin acts to weaken skeletal and smooth muscle by preventing the docking of the acetylcholine vesicle on the inner surface of the presynaptic membrane, thus causing chemical denervation and paresis of skeletal or smooth muscle. We explore the possibility that administration of botulinum toxin may achieve the same effect in bronchial asthma and examine the evidence to support this hypothesis. © 2005 Elsevier Ltd. All rights reserved.|
|Source Title:||Medical Hypotheses|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 21, 2018
WEB OF SCIENCETM
checked on May 9, 2018
checked on Jun 8, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.